Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;19(2):87-88.
doi: 10.1038/s41575-021-00570-x.

Vaccination at the forefront of the fight against hepatitis B and C

Manal H El-Sayed  1 , Jordan J Feld  2
Affiliations
Review

Vaccination at the forefront of the fight against hepatitis B and C

Manal H El-Sayed et al. Nat Rev Gastroenterol Hepatol. 2022 Feb.

Abstract

Vaccination is a key intervention for the elimination of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections to fulfil the WHO’s 2030 global elimination goal. Innovations in 2021 promise to curb HBV transmission by reducing mother-to-child transmission and enhancing vaccine immunogenicity in at-risk adult groups. Additionally, an HCV vaccination trial was conducted, and there were also advances in our understanding of the immunology underpinning the lack of protection against HCV reinfection.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Advances in HBV vaccination in 2021.
a | Integrating hepatitis B virus (HBV) screening and treatment for pregnant women, as well as birth-dose vaccination, into existing facilities for prevention of mother-to-child transmission of HIV. b | A multicentre, randomized controlled trial (PROTECT) of TAV (a tri-antigenic recombinant HBV vaccine) versus MAV (mono-antigenic yeast-derived alum-adjuvanted vaccine). HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen.
See this image and copyright information in PMC

References

    1. World Health Organization. Global hepatitis report, 2017. WHOhttps://www.who.int/publications/i/item/global-hepatitis-report-2017 (2017).
    1. Keane E, Funk AL, Shimakawa Y. Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa. Aliment. Pharmacol. Ther. 2016;44:1005–1017. doi: 10.1111/apt.13795. - DOI - PubMed
    1. Thompson P, et al. Arresting vertical transmission of hepatitis B virus (AVERT-HBV) in pregnant women and their neonates in the Democratic Republic of the Congo: a feasibility study. Lancet Glob. Health. 2021;9:e1600–e1609. doi: 10.1016/S2214-109X(21)00304-1. - DOI - PMC - PubMed
    1. Vesikari T, et al. Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. Lancet Infect. Dis. 2021;21:1271–1281. doi: 10.1016/S1473-3099(20)30780-5. - DOI - PubMed
    1. Atsmon J, et al. Rapid and high seroprotection rates achieved with a tri-antigenic hepatitis B vaccine in healthy young adults: results from a phase IV study. Vaccine. 2021;39:1328–1332. doi: 10.1016/j.vaccine.2020.12.050. - DOI - PubMed

Substances